Cardiogen

Last Updated: May 2026

Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) from the Khavinson bioregulator family, researched for cardiac-tissue-targeted bioregulation, myocardial function, and cardiovascular gene expression. It is one of the synthesized Khavinson compounds with a defined four-amino-acid sequence. Cardiogen is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.

What is Cardiogen and how does the cardiac-targeted bioregulatory mechanism work?

Cardiogen is a synthetic Ala-Glu-Asp-Arg tetrapeptide proposed to enter cardiomyocyte nuclei and modulate gene expression in pathways related to myocardial function, ischemic adaptation, and cardiac tissue maintenance. Within the Khavinson framework, Cardiogen is the cardiac-targeted complement to organ-specific bioregulators like Pinealon (pineal/brain) and Cartalax (cartilage). Preclinical work has reported effects on cardiac gene expression markers and protective effects in rodent ischemia models. Evidence level: Preclinical (rodent cardiac models); Khavinson-group research; independent replication limited.

What does the research show for Cardiogen?

Preclinical rodent studies from the Khavinson group have reported cardioprotective effects in ischemia-reperfusion models, effects on cardiac gene expression markers, and improvements in functional cardiac parameters in aging rodents. Human clinical research at FDA-grade Phase 2/3 standards has not been conducted. Russian clinical use has been reported as part of bioregulator protocols in cardiovascular aging contexts. Evidence level: Preclinical (rodent); Khavinson-group research; FDA-grade Phase 2/3 not conducted.

How does Cardiogen compare to other Khavinson bioregulators?

Cardiogen is the cardiac-targeted tetrapeptide within the Khavinson cluster, distinguished from the tripeptides by an additional terminal amino acid that the Khavinson framework proposes shifts tissue specificity to cardiac tissue. Sequence convention follows the standard pattern.

What are the documented side effects of Cardiogen?

Side effects in available preclinical data and community-reported research use are mild — injection-site reactions are the most common report. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical standards. Evidence level: Preclinical safety; human long-term unestablished.

What is the regulatory status of Cardiogen?

Cardiogen is not approved by the FDA, EMA, or any major Western regulator as of May 2026. Regulatory context in FDA peptide regulation 2025–2026 timeline.

Why does Cardiogen vendor verification matter?

Cardiogen (Ala-Glu-Asp-Arg) shares three of four amino acids with Cartalax (Ala-Glu-Asp) and Epithalon (Ala-Glu-Asp-Gly), making mass spectrometry identity confirmation essential to verify the correct sequence. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Cardiogen vendors?

Peptigrity purchases Cardiogen vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. Methodology in how we calculate trust scores.

Frequently Asked Questions

What does Cardiogen do?

Cardiogen is proposed to act on cardiac tissue through epigenetic gene-expression modulation, with preclinical research focused on cardioprotection in ischemia models and cardiac gene expression markers. Human Phase 2/3 efficacy is not established at Western clinical standards.

Is Cardiogen legal to purchase?

Cardiogen is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.

Will Cardiogen be FDA-approved?

No active FDA approval pathway exists for Cardiogen as of May 2026.

How can I verify a Cardiogen vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Mass spec is essential because Cardiogen shares amino acid composition with related Khavinson peptides. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Cardiogen dose?

No. Cardiogen is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.

Is Cardiogen mechanistically distinct from Western cardiac peptides?

Yes. Cardiogen operates through the proposed Khavinson epigenetic-modulation framework; Western cardiac research peptides like hexarelin work through defined receptor pathways (CD36 in hexarelin's case). They are not mechanistically comparable.

This section is for educational and informational purposes only and does not constitute medical advice. Cardiogen is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.